CXCR1 and lip and oral cavity carcinoma: In a study using the murine oral cancer 2 (MOC2) model, administration of the CXCR1/2 small-molecule inhibitor, SX-682, inhibited MDSC accumulation in the tumor and enhanced the efficacy of NK cell-based adoptive cell transfer therapy [60].